Wall Street Journal reports that Carl Icahn won a seat on Biogen Idec's board of directors, with the results of a possible second seat still up in the air, according to the article. "Icahn, who owns about 5.6% of Biogen and favors its break-up or sale, has claimed his candidates won two seats on Biogen's 13-member board, after a months-long proxy fight that ended Wednesday with a raucous shareholder meeting in Cambridge, Mass.," the article says.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.